Zymeworks (ZYME) Current Deferred Revenue (2021 - 2026)

Zymeworks has reported Current Deferred Revenue for 6 years, with the latest figure at $2.1 million in Q1 2026.

• Quarterly Current Deferred Revenue fell 94.55% year-over-year to $2.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.1 million (down 94.55% YoY) and the FY2025 annual result came in at $2.4 million, down 90.55% from the prior year.
• Current Deferred Revenue retreated to $2.1 million in Q1 2026 per ZYME's latest filing, from $2.4 million in the prior quarter.
• Over five years, Current Deferred Revenue peaked at $41.8 million in Q3 2024 and troughed at $93000.0 in Q3 2023.
• A 5-year average of $16.7 million and a median of $3.8 million in 2025 frame the typical range for Current Deferred Revenue.
• The sharpest annual moves came in 2023 and 2024: Current Deferred Revenue slumped 99.72% in 2023, then jumped 44840.86% in 2024.
• Over 5 years, Current Deferred Revenue stood at $2.4 million in 2022, then surged by 57.25% to $3.7 million in 2023, then surged by 591.89% to $25.6 million in 2024, then plunged by 90.55% to $2.4 million in 2025, then slipped by 14.06% to $2.1 million in 2026.
• According to Business Quant data, Current Deferred Revenue over the past three periods registered $2.1 million, $2.4 million, and $3.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.